These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27734561)

  • 1. Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study.
    Brédart A; Bodson S; Le Tourneau C; Flahault C; Bonnetain F; Beaudeau A; Coquan E; Dolbeault S; Paoletti X
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27734561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dealing with chemotherapy-related symptoms at home: a qualitative study in adult patients with cancer.
    Coolbrandt A; Dierckx de Casterlé B; Wildiers H; Aertgeerts B; Van der Elst E; van Achterberg T; Milisen K
    Eur J Cancer Care (Engl); 2016 Jan; 25(1):79-92. PubMed ID: 25752741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative assessment of the experience of participating in a cancer-related clinical trial.
    Wootten AC; Abbott JM; Siddons HM; Rosenthal MA; Costello AJ
    Support Care Cancer; 2011 Jan; 19(1):49-55. PubMed ID: 19960208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I cancer trials: a qualitative study of specialist palliative care.
    Bellhouse S; Galvin L; Turner L; Taylor S; Davies M; Krebs M; Berman R; Yorke J
    BMJ Support Palliat Care; 2020 Jun; 10(2):234-241. PubMed ID: 31784463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing cancer clinical trial management: recommendations from a qualitative study of trial participants' experiences.
    Cox K
    Psychooncology; 2000; 9(4):314-22. PubMed ID: 10960929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceived control and involvement in self care in patients with colorectal cancer.
    Kidd L; Hubbard G; O'Carroll R; Kearney N
    J Clin Nurs; 2009 Aug; 18(16):2292-300. PubMed ID: 19583662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the quality of life of patients in phase I and II anti-cancer drug trials: interviews versus questionnaires.
    Cox K
    Soc Sci Med; 2003 Mar; 56(5):921-34. PubMed ID: 12593867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation.
    Godskesen T; Nygren P; Nordin K; Hansson M; Kihlbom U
    Support Care Cancer; 2013 Nov; 21(11):3137-42. PubMed ID: 23864288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
    Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expectations and experiences of patients with cancer participating in phase I clinical trials.
    Yoder LH; O'Rourke TJ; Etnyre A; Spears DT; Brown TD
    Oncol Nurs Forum; 1997 Jun; 24(5):891-6. PubMed ID: 9201741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatigue in patients undergoing chemotherapy, their self-care and the role of health professionals: a qualitative study.
    Spichiger E; Rieder E; Müller-Fröhlich C; Kesselring A
    Eur J Oncol Nurs; 2012 Apr; 16(2):165-71. PubMed ID: 21624847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?
    Postel-Vinay S; Gomez-Roca C; Molife LR; Anghan B; Levy A; Judson I; De Bono J; Soria JC; Kaye S; Paoletti X
    J Clin Oncol; 2011 May; 29(13):1728-35. PubMed ID: 21444876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs.
    Rouanne M; Massard C; Hollebecque A; Rousseau V; Varga A; Gazzah A; Neuzillet Y; Lebret T; Soria JC
    Eur J Cancer; 2013 Jan; 49(2):431-8. PubMed ID: 22959468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences.
    Olver IN; Taylor AE; Whitford HS
    Psychooncology; 2005 Jan; 14(1):25-33. PubMed ID: 15386792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How did partners experience cancer patients' participation in a phase I study? An observational study after a patient's death.
    Langenberg SM; Peters ME; van der Graaf WT; Wymenga AN; Prins JB; van Herpen CM
    Palliat Support Care; 2016 Jun; 14(3):241-9. PubMed ID: 26675215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The experience of older patients with cancer in phase 1 clinical trials: a qualitative case series.
    Kvale EA; Woodby L; Williams BR
    Am J Hosp Palliat Care; 2010 Nov; 27(7):474-81. PubMed ID: 20388935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience.
    Molife LR; Alam S; Olmos D; Puglisi M; Shah K; Fehrmann R; Trani L; Tjokrowidjaja A; de Bono JS; Banerji U; Kaye SB
    Ann Oncol; 2012 Aug; 23(8):1968-1973. PubMed ID: 22408187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living with side effects from cancer treatment--a challenge to target information.
    Pedersen B; Koktved DP; Nielsen LL
    Scand J Caring Sci; 2013 Sep; 27(3):715-23. PubMed ID: 23034150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.